Peer Review History

Original SubmissionAugust 7, 2020
Decision Letter - Sabine Rohrmann, Editor

PONE-D-20-24723

Erectile dysfunction and its associated factors among the male population in Adigrat Town, Tigrai Region, Ethiopia: A cross-sectional study

PLOS ONE

Dear Dr. Gebremedhin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

In particular, both reviewers make the point that ED prevalence is rather low, which is likely due to the age of the study participants and the inclusion criteria. This needs further discussion.

Please submit your revised manuscript by Nov 13 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Sabine Rohrmann

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include a copy of Table 4 which you refer to in your text on page 15. (Table 1 2x)

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting study assessing the prevalence of ED in an Ethiopian population. The authors found a prevalence of ED of approximately 25%. Furthermore, the authors found that ED is associated with depression, arterial hypertension and physical inactivity, findings that are in line with the literature.

Some points need to be addressed

1. The prevalence of ED is rather low. This theoretically is attributed to the generally low age of study participants. Indeed this rate is in line with studies assessing the ED prevalence in younger populations. A comment should be made in the discussion section stating that the age of the study participants is rather low and thus the true ED prevalence may be underestimated.

2. Dyslipidemia is a common risk factor for ED. Are there any data regarding the prevalence of dyslipidemia in the study participants? And if yes, was there any association with ED prevalence and severity?

3. Depression is commonly associated with increased risk for ED. Drugs for the treatment of depression are often accompanied by ED as a side effect. Was there any relevant association?

4. Several drugs for the treatment of cardiovascular diseases and risk factors (such as beta-blockers and diuretics) are related with increased risk for ED. If fdata are available, please provide any relevant information regarding the use of such drugs and potential relation with ED prevalence.

5. The manuscript is in need of grammatical revision. Please check.

Reviewer #2: Important is the study by Gebremedhin et. al., which focuses on an often neglected health problem. Often the focus is on diseases that are life-threatening in low-income countries, while the morbidity rate attributable to other non-life-threatening problems is also too high.

- Include the confidence interval of the prevalence in the abstract.

- Census 2007 is too old for a rapidly growing population. Please use predicted population.

- " Who had been engaged in sexual activity in a preceding month " is a defining term for the inclusion of your study participants. This is a strong term that may have excluded many people with erectile dysfunction (ED), which would have increased the prevalence if they had been included. Do not believe that your findings could show a severely underestimated prevalence.

- While your target study participants were individuals, you targeted at a household. This looks a bit superfluous and unnecessary. Other options will have been sought.

- Why was "bivariate regression"? That somehow looks like a tradition. This is necessary if you have a smaller sample but more variables and want to select fewer variables. This is to counteract unstable estimates when you fit more variables into a small sample. However, you have a sufficient sample size for the number of variables. This tradition is also problematic. For example, a variable may not be significant if you perform bivariate regression, but it could have an important interaction effect if you use it with other variables. Do not follow this tradition.

- Minor: I think you can reduce the content of your tables (e.g. in table 2 you can have only one column and one row for each variable. The answers 'Y/N' are not necessary. And you also make the frequency and percentage in one column)

- Quality of life pie chart is not necessary

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Konstantinos Imprialos

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Modified according to the PLOS ONE's style requirements.

2. Please include a copy of Table 4 which you refer to in your text on page 15. (Table 1 2x)

Response: It was a slip of pen that we wrote “Table 4” in both the reference and the title of the table and we have corrected the mistake and revised it to “Table 3” (page 15, line 257-259).

3. The prevalence of ED is rather low. This theoretically is attributed to the generally low age of study participants. Indeed this rate is in line with studies assessing the ED prevalence in younger populations. A comment should be made in the discussion section stating that the age of the study participants is rather low and thus the true ED prevalence may be underestimated.

Response: We agree with this comment. Accordingly, we have stated it in discussion part (page 18, line 281-283).

4. Dyslipidemia is a common risk factor for ED. Are there any data regarding the prevalence of dyslipidemia in the study participants? And if yes, was there any association with ED prevalence and severity?

Response: We accepted the comment and have included it as the limitation of the study in the limitation section of the manuscript (page 19, line 324-326).

5. Depression is commonly associated with increased risk for ED. Drugs for the treatment of depression are often accompanied by ED as a side effect. Was there any relevant association?

Response: Thank you for noticing this. In fact medications used to treat depression have an effect on an individual’s sexual performance, but we omitted them. We have therefore included them as a limitation of the study (page 19, line 324-326).

6. Several drugs for the treatment of cardiovascular diseases and risk factors (such as beta-blockers and diuretics) are related with increased risk for ED. If data are available, please provide any relevant information regarding the use of such drugs and potential relation with ED prevalence.

Response: It is true that medications used to treat cardiovascular disease are important factors for ED, and we have included them in the limitation part of the study (page 19, line 324-326).

7. The manuscript is in need of grammatical revision. Please check.

Response: Checked.

8. Include the confidence interval of the prevalence in the abstract.

Response: We agree with this comment. Accordingly, we have included the confidence interval of the prevalence in the abstract part (page3, line 53).

9. Census 2007 is too old for a rapidly growing population. Please use predicted population.

Response: Thank you for pointing out this and we have updated this with the latest (2017) estimated population of the Town from the report of the Central Statistical Agency of the Federal Democratic Republic of Ethiopia (page 6, line 113-115).

10. " Who had been engaged in sexual activity in a preceding month " is a defining term for the inclusion of your study participants. This is a strong term that may have excluded many people with erectile dysfunction (ED), which would have increased the prevalence if they had been included. Do not believe that your findings could show a severely underestimated prevalence.

Response: The instrument (The International Index of Erectile Function Questionnaire (IIEF-5)) used to determine erectile dysfunction measures the erectile function over the last month and that is why we used sexual activity in the last moth preceding the data collection as inclusion criteria.

11. While your target study participants were individuals, you targeted at a household. This looks a bit superfluous and unnecessary. Other options will have been sought.

Response: Thank you for the suggestion. It was hard to get a list of male individuals in the Town. Instead of selecting individuals from the sampling frame, we used systematic randomized sampling to select study unit (households) and simple randomized sampling to select study participants if we found more than one eligible study participants. In this method, sampling error might be unavoidable, thus minimizing the error that we used the design to maximize sample size.

12. Why was "bivariate regression"? That somehow looks like a tradition. This is necessary if you have a smaller sample but more variables and want to select fewer variables. This is to counteract unstable estimates when you fit more variables into a small sample. However, you have a sufficient sample size for the number of variables. This tradition is also problematic. For example, a variable may not be significant if you perform bivariate regression, but it could have an important interaction effect if you use it with other variables. Do not follow this tradition.

Response: We appreciate your suggestion. We will consider it for the future.

13. Minor: I think you can reduce the content of your tables (e.g. in table 2 you can have only one column and one row for each variable. The answers 'Y/N' are not necessary. And you also make the frequency and percentage in one column) Response: Great point. We have modified our tables accordingly.

14. Quality of life pie chart is not necessary.

Response: Agreed. We removed it.

Attachments
Attachment
Submitted filename: Response to reviewers.docx
Decision Letter - Sabine Rohrmann, Editor

Erectile dysfunction and its associated factors among the male population in Adigrat Town, Tigrai Region, Ethiopia: A cross-sectional study

PONE-D-20-24723R1

Dear Dr. Gebremedhin,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sabine Rohrmann

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Konstantinos Imprialos

Formally Accepted
Acceptance Letter - Sabine Rohrmann, Editor

PONE-D-20-24723R1

Erectile dysfunction and its associated factors among the male population in Adigrat Town, Tigrai Region, Ethiopia: A cross-sectional study

Dear Dr. Gebremedhin:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sabine Rohrmann

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .